A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single (SRD) and Multiple (MRD) Oral TAK-648 Doses in Healthy Japanese Subjects and non Japanese Subjects and subjects with Type 2 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2016
At a glance
- Drugs TAK 648 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- 05 Nov 2016 New trial record